Recently, in a preclinical mouse model of lung cancer, 18A4 antibody has been shown to improve survival and prevent AGR2 induced tumor progression by regulating p53 and MAPK pathways, without any toxic effect on major organs (101, 102). The gene discussed is TP53; the disease is neoplasm.